SYNTAX trial

✅ 1. What does the acronym SYNTAX stand for, and what was the primary aim of the trial?

• SYNTAX = SYNergy between PCI with TAXUS and Cardiac Surgery.
• The trial compared PCI using drug-eluting stents vs. CABG.
• It focused on patients with left main and/or 3-vessel CAD.
• Aim: To assess safety and efficacy of each modality.
• Primary objective was to guide optimal revascularization strategy.

✅ 2. Describe the inclusion criteria for patients enrolled in the original SYNTAX trial.

• Patients with de novo 3-vessel or left main CAD.
• Eligible for both PCI and CABG as per heart team consensus.
• Age ≥18 years, suitable for revascularization.
• No prior revascularization procedures like CABG or PCI.
• Willing and able to provide informed consent.

✅ 3. What were the main differences in outcomes between CABG and PCI at 1 year and 5 years?

• At 1 year, MACCE was higher in PCI vs. CABG.
• Stroke was slightly higher in CABG group.
• At 5 years, mortality was lower in CABG (especially high SYNTAX score).
• Repeat revascularization was more common in PCI.
• CABG had more durable outcomes in complex disease.

✅ 4. What is the significance of the SYNTAX score, and how is it calculated?

• Quantifies coronary lesion complexity.
• Higher score = more complex and diffuse disease.
• Based on location, length, calcification, and bifurcation.
• Helps stratify patients for PCI vs. CABG.
• Widely used in clinical decision-making today.

✅ 5. Which subgroup of patients benefited most from CABG in the SYNTAX trial?

• Patients with SYNTAX score >33.
• Those with complex multivessel CAD.
• Left main disease with diffuse involvement.
• Diabetics with high lesion burden.
• Patients with impaired LV function.

✅ 6. What type of drug-eluting stent was used in the PCI group of the SYNTAX trial?

• First-generation drug-eluting stents.
• Specifically, TAXUS paclitaxel-eluting stents.
• These were standard at the time of the study.
• Less effective than newer-generation DES.
• Contributed to higher revascularization rates.

✅ 7. List three key limitations of the original SYNTAX trial.

• Use of outdated paclitaxel-eluting stents.
• Trial not powered to detect mortality differences alone.
• Exclusion of certain high-risk patient populations.
• Operator expertise variability across centers.
• Lack of newer medical therapy comparison.

✅ 8. What were the major components of the composite primary endpoint used in the trial?

• Death from any cause.
• Stroke.
• Myocardial infarction (MI).
• Repeat revascularization.
• Major Adverse Cardiac and Cerebrovascular Events (MACCE).

✅ 9. How did diabetes mellitus influence outcomes in patients undergoing revascularization?

• Diabetics had worse outcomes overall.
• CABG offered better long-term outcomes than PCI.
• Higher rates of repeat revascularization with PCI.
• Diabetics with complex CAD fared better with surgery.
• Led to guideline changes favoring CABG in diabetics.

✅ 10. How has the SYNTAX trial influenced current guidelines for revascularization in multivessel CAD?

• Validated role of heart team decision-making.
• CABG preferred in high SYNTAX score patients.
• PCI considered for low-to-intermediate complexity.
• Influenced ESC and ACC/AHA guidelines.
• Encouraged development of SYNTAX II and III scores.